Arnon Nagler

TL;DR: It is suggested that the FLAMSA sequential intermediate conditioning regimen provides an efficient disease control in intermediate- and high-risk AML patients, including those in CR2 and with secondary AML.

TL;DR: The results highlight that, in the 10/10 HLA-MUD setting, the use of PTCY for GVHD prophylaxis may provide similar outcomes to those obtained with ATG in patients with AML in CR1.

TL;DR: Reduced-intensity allogeneic stem cell transplantation results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT, and was associated with chemorefractory disease.

TL;DR: Previous results from an interim analysis of an open‐label, randomized, phase 3 study demonstrated that bortezomib combined with pegylated liposomal doxorubicin (PLD) was superior to bortzomib monotherapy in patients with relapsed/refractory multiple myeloma who had previously received one or more lines of therapy.

TL;DR: This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant and shows a good survival in patients alive and in remission at two years, however, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long- term survivors.